Recombinant Human Serum Albumin in Healthy Subjects

NCT05179265 | Completed Phase 1 DMC

• 1 other identifier: rHSA 2020-1
• Study Type: interventional
• Target: 48
• Locations: 1 country
• Sites: 2

Brief Summary

This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum albumin in healthy subjects Kinetics and anti-drug antibody characteristics. Qualified healthy subjects (both male and female) were screened and enrolled to the four dose levels of 2 g, 5 g, 10 g, and 20 g according to the principle of dose escalation, and 6 out of 8 subjects in each dose group One patient received the test drug, and two received a placebo.

Conditions

Hepatic Ascites

Outcome Measures

Primary Outcomes (2)

• TEAE

  Adverse events will be coded using MedDRA (International Dictionary of Medical Terms)., TEAEs related to test drugs were summarized and analyzed according to SOC and PT, and the number of occurrences and the incidence were calculated.

  99 days

• SAE

  Adverse events will be coded using MedDRA (International Dictionary of Medical Terms). SAEs related to test drugs were summarized and analyzed according to SOC and PT, and the number of occurrences and the incidence were calculated.

  99 days

Secondary Outcomes (10)

• AUC0-tlast

  57 days

• Tmax

  57 days

• C0

  1 day

• C8

  1 day

• C15

  1day

Study Arms (2)

Control group

PLACEBO COMPARATOR

0.45 g/bottle，50 mL

Drug: Human serum albumin

test group

EXPERIMENTAL

10 g/bottle (20%, 50 mL)

Drug: recombinant human serum albumin

Interventions

recombinant human serum albumin DRUG

10 g/bottle (20%, 50 mL)

test group

Human serum albumin DRUG

10 g/bottle (20%, 50 mL)

Control group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy adults, 18 to 55 years old (including the critical value), male or female;
• Body weight ≥45 kg, body mass index (BMI) between 18 and 28 kg/㎡ (including the critical value);
• Throughout the study period (from screening to 3 months after the end of the study), subjects or their spouses voluntarily use effective contraceptive methods, such as abstinence, condoms, intrauterine device (IUD), and double barrier method (such as condoms and diaphragm), and there was no sperm donation plan for men;
• Be willing to participate in clinical trials and sign Informed Consent Form;
• Be able to communicate well with researchers and understand and abide by the requirements of this study.

You may not qualify if:

• Yeast source antibody positive;
• Investigators consider that there is a clinically significant drug or food allergy, allergic disease history or allergic constitution (≥2 substance allergies), or explicitly allergic to this product or its similar albumin preparation ingredient;
• History of clinical serious disease, including but not limited to circulatory systems, endocrine systems, gastrointestinal tract, kidneys, nervous systems, blood systems, immune systems, mental disease and metabolic abnormalities, and investigators consider that not suitable for clinical trials ;
• History of cardiovascular system disease, including but not limited to vital signs abnormalities (such as systolic pressure \<90 mmHg or\> 140 mmHg, diastolic pressure \<50 mmHg or\> 90 mmHg, heart rate \<50 bpm or\> 100 bpm), severe arrhythmia, Heart failure, unstable angina pectoris, myocardial infarction occurred six months prior to screening ､the tachycardia / translucent that needs drug therapy, three-degree atrioventricular block, QTC interval≥450 ms or electrocardiogram has a clinically significant abnormality;
• Previous has a chronic infectious disease and the investigators can judge possible affecting the evaluation of the drug in trial;
• Surgery of diseases having clinical significance within 4 weeks before administration;
• Difficulties with blood collection or cannot be resistant to venipuncture , history of needle sickness or blood sickness.
• Alcohol breath test , smoke test or drug urinary screening is positive;
• Physical examination, vital signs, 12 lead electrocardiogram, laboratory examination (blood routine, urine routine, blood biochemical examination, etc.) found that there is a clinical significance;
• One or more positive results for human immunodeficiency virus (HIV) antibody, treponema pallidum antibody, hepatitis B surface antigen or hepatitis C antibody;
• A history of drug abuse, or alcohol abuse ( in other words , drinking more than 14 units of alcohol per week \[1 unit=360 mL beer or 45 mL of 40% alcoholic spirits or 150 mL wine\]) or smoking history (≥5 per day ), or those who cannot smoke during hospitalization;
• Those who use any caffeine-rich food or beverages (coffee, tea, cola, chocolate, etc.) within 48 hours before the first administration of the study drug, or who do not agree to prohibit the use of caffeine-rich food or beverages during the trial;
• Those who have special dietary requirements and cannot follow a unified diet;
• Those who have been treated with corticosteroids or human plasma products within 4 weeks before the trial drug is administered, and have used any prescription drugs, over-the-counter drugs or herbal medicines within 2 weeks (except external preparations or topical preparations);
• Participated in any drug clinical trial within 3 months before administration;

Sponsors & Collaborators

• Protgen Ltd: lead

Study Sites (2)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100000, China

Location

Shenzhen Protgen Co., Ltd.

Shenzhen, Guangdong, 100084, China

Location

MeSH Terms

Interventions

recombinant human serum albumin-heme; Serum Albumin, Human

Intervention Hierarchy (Ancestors)

Serum Albumin; Albumins; Proteins; Amino Acids, Peptides, and Proteins; Blood Proteins

Study Officials

• Bei Hu, Ph.D

  hubei01_pumch@163.com

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Masking Details: double-blind
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 2, 2021
• First Posted: January 5, 2022
• Study Start: March 29, 2021
• Primary Completion: July 7, 2022
• Study Completion: July 7, 2022
• Last Updated: March 11, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CN (2)